TLR7/TLR8 Agonist - Imidazoquinoline compound

R848 (Resiquimod), an imidazoquinoline, is a dual TLR7 and TLR8 synthetic agonist with potent antiviral activity [1-3]. It induces differential TLR7 and/or TLR8 responses in human and murine immune cells. TLR7 and TLR8 are endosomal pattern recognition receptors that play an important role in the antiviral immune response.

Mode of action

R848 (Resiquimod), a low molecular weight synthetic molecule, acts as a selective activating ligand for both TLR7 and TLR8 in humans but only TLR7 in mice. It activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway with the subsequent activation of the transcription factors NF-κB and interferon regulatory factor (IRF) [2, 3]. This ultimately leads to the production of pro-inflammatory cytokines and type I interferons. 

Unlike other commercially available R848 preparations, InvivoGen's R848 is water soluble, validated for TLR7/TLR8 potency, and tested to ensure the absence of TLR2 or TLR4 contamination. 

InvivoGen also offers R848 VacciGrade™, a high-quality pre-clinical grade suited for in vivo studies. 

Key features of R848

• Agonist of hTLR7 and hTLR8
• Agonist of mTLR7
• Each lot is highly pure (≥95%) and functionally tested
• High-quality, pre-clinical R848 VacciGrade™ is also available for in vivo studies